Skip to main content

Table 5 Differentiation of bio-activities (pIC50), prediction inhibition, and residual of model 4

From: In silico studies of some 2-anilinopyrimidine derivatives as anti-triple-negative breast cancer agents

Name

pIC50

Predicted IC50

Residual

1

4.26

4.1979

0.0621

2*

4.07

4.1064

− 0.0364

3

4.24

4.1818

0.0582

4*

4.06

4.1625

− 0.1025

5

4.13

4.1719

0.0419

6

4.19

4.1616

0.0284

7

4.11

4.2327

− 0.1227

8*

4.09

4.0429

0.0471

9

4.25

4.2148

0.0352

10

4.14

4.1386

0.0014

11

4.14

4.1807

− 0.0407

12*

4.35

4.2090

0.1400

13*

4.29

4.6054

− 0.3155

14

4.21

4.2225

− 0.0125

15

4.67

4.6575

0.0125

16

4.21

4.1851

0.0249

17

4.20

4.1708

0.0292

18

4.28

4.2991

− 0.0191

19

4.11

4.1178

− 0.0078

20

4.11

4.1578

− 0.0478

21

4.24

4.2204

0.0196

22

4.16

4.1488

0.0112

23*

4.44

4.2092

0.2308

24

4.27

4.2534

0.0166

25*

4.10

4.1705

− 0.0704

26*

4.60

4.1940

− 0.1340

27

4.19

4.2215

− 0.0315

28

4.16

4.1405

0.0195

29

4.21

4.2047

0.0053

30*

4.77

4.6569

0.1131

  1. The compounds with an asterisk symbol (*) are the test set while the compounds without an asterisk symbol (*) are the train set